[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Bioage Labs Inc (BIOA)

Bioage Labs Inc (BIOA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,005,527
  • Shares Outstanding, K 44,453
  • Annual Sales, $ 9,000 K
  • Annual Income, $ -80,610 K
  • EBIT $ -102 M
  • EBITDA $ -102 M
  • 60-Month Beta 0.94
  • Price/Sales 112.83
  • Price/Cash Flow N/A
  • Price/Book 2.67

Options Overview Details

View History
  • Implied Volatility 109.81% (+0.08%)
  • Historical Volatility 79.05%
  • IV Percentile 40%
  • IV Rank 12.91%
  • IV High 511.33% on 11/19/25
  • IV Low 50.29% on 09/17/25
  • Expected Move (DTE 21) 1.36 (5.72%)
  • Put/Call Vol Ratio 0.07
  • Today's Volume 81
  • Volume Avg (30-Day) 386
  • Put/Call OI Ratio 0.12
  • Today's Open Interest 11,298
  • Open Int (30-Day) 8,569
  • Expected Range 22.40 to 25.12

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 10 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.65
  • Number of Estimates 5
  • High Estimate $-0.54
  • Low Estimate $-0.75
  • Prior Year $-0.60
  • Growth Rate Est. (year over year) -8.33%

Price Performance

See More
Period Period Low Period High Performance
1-Month
15.14 +56.99%
on 06/10/26
24.93 -4.69%
on 06/25/26
+7.56 (+46.67%)
since 05/26/26
3-Month
14.73 +61.36%
on 05/19/26
24.93 -4.69%
on 06/25/26
+7.51 (+46.22%)
since 03/26/26
52-Week
4.07 +484.50%
on 07/01/25
24.93 -4.69%
on 06/25/26
+19.40 (+444.95%)
since 06/26/25

Most Recent Stories

More News
BioAge Labs Announces First Participant Dosed in QUELL-CV, a Phase 2 Proof-of-Concept Trial of BGE-102, a Novel Oral NLRP3 Inhibitor, in Patients at Elevated Cardiovascular Risk

Randomized, double-blind, placebo-controlled, dose-ranging trial evaluating three once-daily oral doses of BGE-102 in participants with elevated systemic inflammation and additional cardiovascular risk...

BIOA : 23.76 (+5.04%)
BioAge Labs Eyes Key BGE-102 Readouts in Heart Risk and Diabetic Eye Disease

BioAge Labs (NASDAQ:BIOA) executives used a fireside chat at the Jefferies 2026 Global Healthcare Conference to outline the company’s plans for BGE-102, its lead NLRP3 inhibitor, with near-term readouts...

BIOA : 23.76 (+5.04%)
BioAge Labs to Present at Upcoming Investor Conferences

EMERYVILLE, Calif., May 22, 2026 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (NASDAQ: BIOA) ("BioAge", "the Company"), a clinical-stage biotechnology company developing therapeutic product candidates for metabolic...

BIOA : 23.76 (+5.04%)
Cell-Based Therapies Poised to Disrupt Multi-Billion-Dollar Anti-Aging and Neurodegenerative Markets

EQNX::TICKER_START (OTCQB:AVAI),(NASDAQ:GERN),(NASDAQ:BIOA),(NYSE:LCTX),(NASDAQ:FATE) EQNX::TICKER_END

AVAI : 0.1600 (+10.27%)
BIOA : 23.76 (+5.04%)
LCTX : 1.2800 (+4.92%)
GERN : 1.3200 (-3.65%)
FATE : 2.1000 (+12.30%)
BioAge Labs Enters Its First Quarter Judged Entirely on Pipeline Execution

Barchart Research What to Expect from BIOA Earnings BIOA Generated May 11, 2026 Current Price $18.16 EPS Estimate $$-0.69 Consensus Rating Moderate Buy Average Move 6.27% BioAge Labs Enters Its First Quarter...

BIOA : 23.76 (+5.04%)
BioAge Labs R&D Day: BGE-102 Phase I Shows Big hs-CRP Drops, Sets Up Cardio & DME POC Trials

BioAge Labs (NASDAQ:BIOA) used its R&D Day event to provide an update on its lead program, BGE-102, an oral, brain-penetrant inhibitor of the NLRP3 inflammasome that the company is developing across cardiovascular...

BIOA : 23.76 (+5.04%)
BioAge Labs Reports First Quarter 2026 Financial Results and Provides Business Updates

Positive topline Phase 1 data for BGE-102, demonstrating potential best-in-class reductions among oral NLRP3 inhibitors in inflammatory biomarkers of cardiovascular risk Phase 2 dose-ranging proof-of-concept...

BIOA : 23.76 (+5.04%)
Can BioAge Labs Break Its Pattern of Wider Losses Before Tomorrow's Report?

Barchart Research What to Expect from BIOA Earnings BIOA Generated May 4, 2026 Current Price $16.62 EPS Estimate $$-0.71 Consensus Rating Moderate Buy Average Move 6.27% Can BioAge Labs Break Its Pattern...

BIOA : 23.76 (+5.04%)
BioAge to Host R&D Day Focused on NLRP3 Inhibition on May 8, 2026

Live webcast on Friday, May 8, 2026, beginning at 12:30 PM ET Event will feature Phase 1 clinical data for BGE-102 and the therapeutic rationale for development in atherosclerotic cardiovascular disease...

BIOA : 23.76 (+5.04%)
BioAge Reports Positive Phase 1 Data for BGE-102, a Novel Oral NLRP3 Inhibitor, Demonstrating Potential Best-in-Class Reductions in hsCRP

120 mg and newly announced 60 mg once-daily doses each achieved ≥85% median hsCRP reductions in participants with obesity and elevated baseline inflammation BGE-102 was well tolerated across all...

BIOA : 23.76 (+5.04%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

Relative Strength is above 70%. The market is in overbought territory. Watch for a potential trend reversal.

See More Share

Business Summary

BioAge Labs Inc. is a clinical-stage biopharmaceutical company. It involved in developing therapeutic product candidates for metabolic diseases, such as obesity, by targeting the biology of aging. BioAge Labs Inc. is based in RICHMOND, Calif.

See More

Key Turning Points

3rd Resistance Point 25.71
2nd Resistance Point 24.77
1st Resistance Point 24.26
Last Price 23.76
1st Support Level 22.81
2nd Support Level 21.87
3rd Support Level 21.36

See More

52-Week High 24.93
Last Price 23.76
Fibonacci 61.8% 16.96
Fibonacci 50% 14.50
Fibonacci 38.2% 12.04
52-Week Low 4.07

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.